TrialThe Lancet. Infectious diseases2018

Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.

John H Beigel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.